Cargando…

Partial agonism improves the anti-hyperglycaemic efficacy of an oxyntomodulin-derived GLP-1R/GCGR co-agonist

OBJECTIVE: Glucagon-like peptide-1 and glucagon receptor (GLP-1R/GCGR) co-agonism can maximise weight loss and improve glycaemic control in type 2 diabetes and obesity. In this study, we investigated the cellular and metabolic effects of modulating the balance between G protein and β-arrestin-2 recr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pickford, Phil, Lucey, Maria, Rujan, Roxana-Maria, McGlone, Emma Rose, Bitsi, Stavroula, Ashford, Fiona B., Corrêa, Ivan R., Hodson, David J., Tomas, Alejandra, Deganutti, Giuseppe, Reynolds, Christopher A., Owen, Bryn M., Tan, Tricia M., Minnion, James, Jones, Ben, Bloom, Stephen R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8163982/ https://www.ncbi.nlm.nih.gov/pubmed/33933675 http://dx.doi.org/10.1016/j.molmet.2021.101242

Ejemplares similares

Structural analysis of the dual agonism at GLP-1R and GCGR
por: Li, Yang, et al.
Publicado: (2023)

Increased food intake with oxyntomodulin analogues
por: Price, Samantha L., et al.
Publicado: (2015)

Oxyntomodulin analogue increases energy expenditure via the glucagon receptor
por: Scott, R., et al.
Publicado: (2018)

Unraveling oxyntomodulin, GLP1's enigmatic brother
por: Pocai, Alessandro
Publicado: (2012)

Evaluation of efficacy- versus affinity-driven agonism with biased GLP-1R ligands P5 and exendin-F1
por: Marzook, Amaara, et al.
Publicado: (2021)

Disconnect between signalling potency and in vivo efficacy of pharmacokinetically optimised biased glucagon-like peptide-1 receptor agonists
por: Lucey, Maria, et al.
Publicado: (2020)

Signalling, trafficking and glucoregulatory properties of glucagon‐like peptide‐1 receptor agonists exendin‐4 and lixisenatide
por: Pickford, Philip, et al.
Publicado: (2020)

Investigating the Glucagon Receptor and Glucagon-Like Peptide 1 Receptor Activity of Oxyntomodulin-Like Analogues in Male Wistar Rats
por: Price, Samantha L., et al.
Publicado: (2015)

Ligand-Receptor Interactions and Machine Learning in GCGR and GLP-1R Drug Discovery
por: Mizera, Mikołaj, et al.
Publicado: (2021)

Ligand-Specific Factors Influencing GLP-1 Receptor Post-Endocytic Trafficking and Degradation in Pancreatic Beta Cells
por: Fang, Zijian, et al.
Publicado: (2020)

Action and therapeutic potential of oxyntomodulin()
por: Pocai, Alessandro
Publicado: (2013)

Design of a highly potent GLP-1R and GCGR dual-agonist for recovering hepatic fibrosis
por: Song, Nazi, et al.
Publicado: (2022)

Striking the Balance: GLP-1/Glucagon Co-Agonism as a Treatment Strategy for Obesity
por: Hope, David C. D., et al.
Publicado: (2021)

Selective polypeptide ligand binding to the extracellular surface of the transmembrane domains of the class B GPCRs GLP-1R and GCGR
por: Wang, Huixia, et al.
Publicado: (2023)

Ureidopeptide GLP-1 analogues with prolonged activity in vivo via signal bias and altered receptor trafficking
por: Fremaux, Juliette, et al.
Publicado: (2019)

The therapeutic potential of GLP‐1 receptor biased agonism
por: Jones, Ben
Publicado: (2021)

Agonist-induced membrane nanodomain clustering drives GLP-1 receptor responses in pancreatic beta cells
por: Buenaventura, Teresa, et al.
Publicado: (2019)

Oxyntomodulin regulates resetting of the liver circadian clock by food
por: Landgraf, Dominic, et al.
Publicado: (2015)

Resolution of NASH and hepatic fibrosis by the GLP-1R/GcgR dual-agonist Cotadutide via modulating mitochondrial function and lipogenesis.
por: Boland, Michelle L., et al.
Publicado: (2020)

BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy
por: Zimmermann, Tina, et al.
Publicado: (2022)

GLP-1/glucagon receptor co-agonism for treatment of obesity
por: Sánchez-Garrido, Miguel A., et al.
Publicado: (2017)

Oxyntomodulin increases intrinsic heart rate through the glucagon receptor
por: Mukharji, Auyon, et al.
Publicado: (2013)

Hyperglycaemic Hemichorea
por: Marques, Joana Silva, et al.
Publicado: (2018)

Cardiovascular Benefits of GLP-1 Receptor Agonism: Is Inflammation a Key?
por: Marx, Nikolaus, et al.
Publicado: (2018)

PYY(3–36) and Oxyntomodulin Can Be Additive in Their Effect on Food Intake in Overweight and Obese Humans
por: Field, Benjamin C.T., et al.
Publicado: (2010)

The Glucagon Receptor Is Involved in Mediating the Body Weight-Lowering Effects of Oxyntomodulin
por: Kosinski, Jennifer R., et al.
Publicado: (2012)

A glucagon analogue decreases body weight in mice via signalling in the liver
por: Hinds, Charlotte E., et al.
Publicado: (2021)

Molecular dynamics studies reveal structural and functional features of the SARS‐CoV‐2 spike protein
por: Pipitò, Ludovico, et al.
Publicado: (2022)

The Effect of a Subcutaneous Infusion of GLP-1, OXM, and PYY on Energy Intake and Expenditure in Obese Volunteers
por: Tan, Tricia, et al.
Publicado: (2017)

The Extracellular Surface of the GLP-1 Receptor Is a Molecular Trigger for Biased Agonism
por: Wootten, Denise, et al.
Publicado: (2016)

Anorectic and aversive effects of GLP-1 receptor agonism are mediated by brainstem cholecystokinin neurons, and modulated by GIP receptor activation
por: Costa, Alessia, et al.
Publicado: (2021)

Enhanced Endosomal Signaling and Desensitization of GLP-1R vs GIPR in Pancreatic Beta Cells
por: Manchanda, Yusman, et al.
Publicado: (2023)

Receptor Activity-Modifying Protein 2 (RAMP2) alters glucagon receptor trafficking in hepatocytes with functional effects on receptor signalling
por: McGlone, Emma Rose, et al.
Publicado: (2021)

GLP-2 receptor signaling controls circulating bile acid levels but not glucose homeostasis in Gcgr(−/−) mice and is dispensable for the metabolic benefits ensuing after vertical sleeve gastrectomy
por: Patel, Anita, et al.
Publicado: (2018)

“Let's Stay Together”; GIP and GLP-1 dual agonism in the treatment of metabolic disease
por: DiMarchi, Richard D.
Publicado: (2018)

The Effects of Dual GLP-1/GIP Receptor Agonism on Glucagon Secretion—A Review
por: Mathiesen, David S., et al.
Publicado: (2019)

A GLP-1:CCK fusion peptide harnesses the synergistic effects on metabolism of CCK-1 and GLP-1 receptor agonism in mice
por: Hornigold, David C., et al.
Publicado: (2018)

Glucagon Potentiates Insulin Secretion Via β-Cell GCGR at Physiological Concentrations of Glucose
por: Zhang, Yulin, et al.
Publicado: (2021)

GLP-1R Agonism Enhances Adjustable Gastric Banding in Diet-Induced Obese Rats
por: Habegger, Kirk M., et al.
Publicado: (2013)

RAMP2 Influences Glucagon Receptor Pharmacology via Trafficking and Signaling
por: Cegla, Jaimini, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_aomj7djt90co1b71ftfb5mqgg7